Midazolam: Safety of use in palliative care

Biomedicine & Pharmacotherapy

Mary-Tiffany Oduah¹  Krzysztof Szymański²  Iwona Zaporowska-Stachowiak³  Maciej Sopata⁴  Jacek Łuczak⁵  Katarzyna Stachowiak-Szymczak⁶ 

[1] Corresponding author at: Chair and Department of Pharmacology, Poznan University of Medical Sciences, Poland.;Palliative Medicine In-Patient Unit, University Hospital of Lord’s Transfiguration, Poznan University of Medical Sciences, Poland;Chair and Department of Pharmacology, Poznan University of Medical Sciences, Poland;Department of Interpreting Studies and Audiovisual Translation, Institute of Applied Linguistics, University of Warsaw, Poland;English Students’ Research Association, Poznan University of Medical Sciences, Poland;Students' Scientific Society, Poznan University of Medical Sciences, Poznań, Poland;

关键词: Midazolam;    Drug-drug interactions;    Palliative care;    Pharmacokinetics;    Palliative sedation;    Context-sensitive half-life;   

DOI  :  

来源: DOAJ

【 摘 要 】

Purpose: The undesired effects of midazolam can be life-threatening. This paper delineates the findings related to the pharmacokinetics, adverse effects and drug-drug interactions as well as associated therapeutic implications for safe midazolam use. Methods: A systematic review of literature was conducted. Results: The pharmacokinetics of midazolam depends on hepatic and renal functions, fat tissue mass, route and duration of administration, as well as potential drug-drug interactions. Palliative care patients constitute a high-risk group prone to side effects of drugs, due to polytherapy and multi-organ failure. Conclusion: Midazolam is one of three most frequently administered drugs in palliative care. The indications for its use include anxiety, dyspnea, seizures, vomiting refractory to treatment, agitation, myoclonus, status epilepticus, restlessness, delirium, pruritus, hiccups, insomnia, analgosedation, palliative sedation and preventing or counteracting undesired effects of ketamine.

【 授权许可】

Unknown